

Sanofi
Form 6-K
June 04, 2015

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2015

Commission File Number: 001-31368

SANOFI

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F ☒ x

Form 40-F ☐ o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ o

No ☒ x

If ☒ Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: Sanofi - Form 6-K

In May and June 2015, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated May 21, 2015: Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Exhibit 99.2	Press release dated May 26, 2015: Sanofi Appoints Suresh Kumar to the Executive Committee and Executive Vice President, External Affairs
Exhibit 99.3	Press release dated June 4, 2015: FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 4, 2015

SANOFI

By /S/ John Felitti

Name:

Title:

John Felitti

Associate Vice President,

Corporate Law, Financial & Securities Law

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated May 21, 2015: Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Exhibit 99.2	Press release dated May 26, 2015: Sanofi Appoints Suresh Kumar to the Executive Committee and Executive Vice President, External Affairs
Exhibit 99.3	Press release dated June 4, 2015: FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa